Drugs / Ompenaclid
Ompenaclid
also known as
RGX-202 · 3-guanidino-propionic acid · Amidino beta-alanine · Beta-guanidinopropionic acid · N-carbamimidoyl-.beta.-alanine · Ompenaclid hemisuccinate · OMPENACLID SUCCINATE · Oristar gpa · +3 more
Small molecule targets SLC6A8 via inhibition
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03597581 | Jun 2018 → Mar 2025 | colorectal carcinoma, gastric cancer | Inspirna, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05983367 | Oct 2023 → Jan 2025 | metastasis from malignant tumor of colon | Inspirna, Inc. | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05693142 | Jan 2023 → Aug 2026 overdue | Duchenne muscular dystrophy | REGENXBIO Inc. | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07652606 Background | — | — | REGENXBIO Inc. | Temporarily not available | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ompenaclid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03597581 ↗ |
| Known as | 3-guanidino-propionic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL20489 ↗ |
| Known as | Amidino beta-alanine | ChEMBL registry synonym — accepted as the source's own label CHEMBL20489 ↗ |
| Known as | Beta-guanidinopropionic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL20489 ↗ |
| Known as | N-carbamimidoyl-.beta.-alanine | ChEMBL registry synonym — accepted as the source's own label CHEMBL20489 ↗ |
| Known as | Ompenaclid hemisuccinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL20489 ↗ |
| Known as | OMPENACLID SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL20489 ↗ |
| Known as | Oristar gpa | ChEMBL registry synonym — accepted as the source's own label CHEMBL20489 ↗ |
| Known as | PNU-10483 | ChEMBL registry synonym — accepted as the source's own label CHEMBL20489 ↗ |
| Known as | RGX-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07652606 ↗ |
| Known as | RGX-202 hemisuccinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL20489 ↗ |
| Known as | RGX-202-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL20489 ↗ |
| Action | Inhibit | “RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.” NCT03597581 ↗ |
| Modality | Small molecule | “RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.” NCT03597581 ↗ |
| Route | Intravenous | “a one-time intravenous (IV) dose of RGX-202” NCT05693142 ↗ |
| Target | SLC6A8 | “RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.” NCT03597581 ↗ |